Classifications: mucous membrane; antiinflammatory agent; Therapeutic: antiinflammatory; gi
Pregnancy Category: C
250 mg capsules
Converted to 5-aminosalicylic acid (5-ASA) by colonic bacteria. The 5-ASA is absorbed slowly, resulting in a very high local
concentration in the colon. 5-ASA inhibits prostaglandin production in the colon, thus leading to anti-inflammatory properties
of the drug.
5-ASA has antiinflammatory activity in ulcerative colitis.
Maintenance therapy in patients with ulcerative colitis.
Acute flare-up of ulcerative colitis.
Hypersensitivity to salicylates or 5-ASA; pregnancy (category C).
Patients with preexisting kidney disease; lactation. Safety and effectiveness in children are not established.
Route & Dosage
Adult: PO 500 mg b.i.d., may increase up to 1.53 g/d in 24 divided doses
- Give with food in two evenly divided doses.
Adverse Effects (≥1%)CNS:
Headache. GI: Diarrhea,
nausea, abdominal pain, indigestion
, vomiting, bloating. Skin:
Rash. Body as a Whole: Arthralgia
13% from GI tract; high colonic concentrations are associated with efficacy
Olsalazine, a prodrug, is composed of 2 molecules of 5-ASA; colonic bacterial azo-reductases break the azo bond, releasing
2 active molecules of 5-ASA. Elimination:
Primarily in feces as 5-ASA. Half-Life:
At least 6 h.
Assessment & Drug Effects
- Monitor kidney function in patients with preexisting renal disease.
- Monitor for S&S of a hypersensitivity reaction (see Appendix F). Withhold olsalazine and notify physician at first sign of
an allergic response.
Patient & Family Education
- Report diarrhea, a possible adverse effect, to the physician.